ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
62,966.75
-0.13%
S&P 500
5,214.08
0.51%
Dow Jones
39,387.76
0.85%
US Dollar vs Yen
155.7715
0.24%
Brent Oil
84.195
0.29%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Acer Therapeutics Inc (ACER)

  7. Acer Therapeutics Inc (ACER) ニュース

ACER

Acer Therapeutics (ACER)

Acer Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:ACER
日付受信時刻ニュースソース見出しコード企業名
2023/11/0906 : 13Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:ACERAcer Therapeutics Inc
2023/11/0906 : 11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACERAcer Therapeutics Inc
2023/11/0221 : 51Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ACERAcer Therapeutics Inc
2023/11/0221 : 50Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:ACERAcer Therapeutics Inc
2023/11/0221 : 49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACERAcer Therapeutics Inc
2023/11/0221 : 30GlobeNewswire Inc.Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related ProposalsNASDAQ:ACERAcer Therapeutics Inc
2023/10/3020 : 24Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ACERAcer Therapeutics Inc
2023/10/1106 : 17Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:ACERAcer Therapeutics Inc
2023/08/3122 : 29Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:ACERAcer Therapeutics Inc
2023/08/3122 : 26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACERAcer Therapeutics Inc
2023/08/3120 : 30GlobeNewswire Inc.Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial ProductNASDAQ:ACERAcer Therapeutics Inc
2023/08/3105 : 05GlobeNewswire Inc.Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical EuropeNASDAQ:ACERAcer Therapeutics Inc
2023/08/1505 : 19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACERAcer Therapeutics Inc
2023/08/1505 : 09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACERAcer Therapeutics Inc
2023/08/1505 : 05GlobeNewswire Inc.Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ACERAcer Therapeutics Inc
2023/06/2622 : 01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
2023/06/2621 : 30GlobeNewswire Inc.Acer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and FounderNASDAQ:ACERAcer Therapeutics Inc
2023/06/0805 : 03Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
2023/05/2305 : 17Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
2023/05/1606 : 29Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ACERAcer Therapeutics Inc
2023/05/1606 : 22Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
2023/05/1606 : 10GlobeNewswire Inc.Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate UpdateNASDAQ:ACERAcer Therapeutics Inc
2023/05/0419 : 00Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
2023/05/0122 : 02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
2023/05/0121 : 30GlobeNewswire Inc.Acer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahead of ScheduleNASDAQ:ACERAcer Therapeutics Inc
2023/04/2719 : 25Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(2) (424b2)NASDAQ:ACERAcer Therapeutics Inc
2023/04/1505 : 29Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:ACERAcer Therapeutics Inc
2023/03/2805 : 18Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:ACERAcer Therapeutics Inc
2023/03/2805 : 13Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ACERAcer Therapeutics Inc
2023/03/2805 : 01GlobeNewswire Inc.Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate UpdateNASDAQ:ACERAcer Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ACER

最近閲覧した銘柄

USOTC
ADDYY
Adidas (QX)
NYSE
XOM
Exxon Mobil
CCOM
US30
US 30
FX
USDGBP
US Dollar vs Sterling
USI
USTECH100
US Tech 100
FX
USDJPY
US Dollar vs Yen
NYSE
MRK
Merck
SPI
SP500
S&P 500
NASDAQ
AMZN
Amazon.com
USOTC
RHHBY
Roche (QX)
NASDAQ
TSLA
Tesla
PM
XAUUSD
Gold vs US Dollar
CCOM
SILVER
SILVER
AMEX
XLE
Energy Select Sector SPDR
FX
USDEUR
US Dollar vs Euro
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有